In-depth review of the cardiovascular and metabolic markets, including analysis and comparison of key sales trends in the therapy areas of diabetes, dyslipidemia, hypertension and thrombosis over the forecast (2010–19) period.
In the wake of Lipitor’s patent expiry, the dyslipidemia market continues to face increasing genericization leading to falling sales in key drug classes.
This in-depth Excel databook covers the metabolic and endocrinology pipeline by company and phase.
This in-depth Excel databook covers the cardiovascular pipeline by company and phase.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions